Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CAH vs SNYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAH Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

CAH Overall Winner 6-Pillar Tally: CAH 4 – 2 SNYR Matrix Metrics: CAH 7 – 3 SNYR

As of Nov 20, 2026, Cardinal Health, Inc. (CAH) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CAH carries a Unified Composite Score of 42.7/100 (HOLD) at $272.81 (22.6x Forward P/E, 1.3% operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin).

  • Composite vs. Pillar Nuance: While SNYR currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. CAH 42.7/100 HOLD), CAH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (1.3% vs. -10.3% operating margin) and revenue trajectory (+5.5% vs. -32.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAH vs SNYR
CAH NYSE Head-to-Head Winner
Cardinal Health, Inc.
Wholesale-Drugs, Proprietaries & Druggists' Sundries
$272.81
+0.17% 1D
Market Cap $62.9B
TTM Revenue $257.8B
Forward P/E 22.6x
Beta / 30D Vol -0.03β · 24% Vol
Unified Composite Score
42.7 / 100 HOLD
Tech 24.0 Fund 39.0 Flow 59.0 Mom 36.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.9% over 20 days), RSI 61
RSI-14: 61.2 · SMA20: $266.37 · SMA50: $247.95
SNYR NASDAQ
Synergy CHC Corp. Common Stock
Medicinal Chemicals & Botanical Products
$0.09
-67.02% 1D
Market Cap $4.1M
TTM Revenue $28M
Forward P/E 0.6x
Beta / 30D Vol -0.86β · 868% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 55.0 Fund 39.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $0.11 · SMA50: $0.14

6-Pillar Scorecard Institutional Category Breakdown (CAH 4 – 2 SNYR)

Columns: Metric · CAH · SNYR
1. Valuation Multiples SNYR
Forward P/E 22.6x 0.6x
Trailing P/E 35.2x 0.6x
PEG Ratio 1.31x N/M
EV / Revenue 0.3x 0.1x
2. Growth & Scale CAH
Revenue Growth (YoY) +5.5% -32.8%
Earnings Growth (YoY) +26.6% -90.6%
TTM Revenue (USD) $257.8B $28M
Market Cap $62.9B $4.1M
3. Profitability & Quality CAH
Gross Margin 3.9% 65.4%
Operating Margin 1.3% -10.3%
Net Profit Margin 0.7% -57.0%
Return on Equity (ROE) 0.0% -361.1%
4. Balance Sheet & Cash Flow CAH
Cash Generation (TTM) $4.90B -$3.8M
Cash Flow Margin 1.9% -13.7%
Net Cash / Leverage $3.55B Net Debt -361.1% ROE
Dividend Yield 0.74% None (0.00%)
5. Options & Positioning CAH
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 82.4% (59th %ile) N/A (N/A)
Put/Call OI Skew 1.00x (Balanced) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SNYR
OpEx & R&D Intensity 2.6% of Rev ($6.70B) 75.7% of Rev ($21M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Distribution Operator Medical Distribution Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAH (7) vs SNYR (3)
Institutional Metric CAH SNYR Criterion Row Edge
Market Capitalization
Scale
$62.9B $4.1M Larger Scale CAH
Trailing P/E Ratio
Valuation
35.2x 0.6x Lower Multiple SNYR
Forward P/E Ratio
Valuation
22.6x 0.6x Lower Multiple SNYR
Revenue Growth (YoY)
Growth
+5.5% -32.8% Higher Growth CAH
Operating Margin (TTM)
Profitability
1.3% -10.3% Higher Margin CAH
Net Profit Margin
Profitability
0.7% -57.0% Higher Margin CAH
Return on Equity (ROE)
Capital Efficiency
0.0% -361.1% Higher ROE CAH
52-Week Range Position
Momentum
87% ($180–$286) 1% ($0–$3) Stronger Trend CAH
Beta / 30D Volatility
Risk Regime
-0.03β · 24% Vol -0.86β · 868% Vol Lower Realized Risk CAH
Unified Institutional Score
Composite Signal
42.7 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite SNYR
Trailing 12M Revenue (USD)
Operating Scale
$257.8B $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.9% 65.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.31x PEG · 0.3x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$4.90B ($3.55B Net Debt) -$3.8M (-361.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAH +12.6 pp
CAH: -3.68% · SNYR: -16.28%
3M Horizon CAH +56.67 pp
CAH: +0.03% · SNYR: -56.64%
6M Horizon CAH +100.03 pp
CAH: +6.83% · SNYR: -93.2%
1Y Horizon CAH +105.2 pp
CAH: +9.07% · SNYR: -96.13%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CAH Revenue SNYR Revenue CAH Op. Margin SNYR Op. Margin Margin Leader
FY2019 $145.5B $30M 1.4% -27.1% CAH
FY2020 $152.9B N/A -2.7% N/A CAH
FY2021 $162.5B N/A 0.3% N/A CAH
FY2022 $181.3B N/A -0.3% N/A CAH
FY2023 $205.0B $40M 0.4% 25.3% SNYR
FY2024 $226.8B $30M 0.5% 16.7% SNYR
FY2025 $222.6B $30M 1.0% -27.8% CAH
FY2026 $254.2B N/A 1.0% N/A CAH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAH BREAKOUT
97d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 59th %ile
Put/Call OI Skew 1.00x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CAH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SNYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $283.85 · IV 27.2%

CAH Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($28,385)

Compare $28,385 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 27.2% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $280 / $300 Bull Call Spread

Buy 1x $280C · Sell 1x $300C · 31d

Net Entry $851 Debit
T+5d @ +5% Move +$501 (+59%)
Max Risk / Buffer $851 Capped
5d Edge & Liquidity 0.9x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $260 / $240 Bull Put Spread

Sell 1x $260P · Buy 1x $240P · 59d

Net Entry $252 Credit
Max Credit / Yield +$252 (+14.4% RoM)
Max Risk / Buffer -9.3% Cushion ($1,748 Mgn)
5d Edge & Liquidity 81% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAH Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $62.9B market capitalization and 1.3% operating margin.
OpEx & R&D Reinvestment 2.6% of Rev ($6.70B)
90D Engineering Disclosures 0 Published
SNYR Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $4.1M market capitalization and -10.3% operating margin.
OpEx & R&D Reinvestment 75.7% of Rev ($21M)
90D Engineering Disclosures 0 Published

Investor FAQ CAH vs SNYR Key Questions & Quantitative Answers

As of Nov 20, 2026, Cardinal Health, Inc. (CAH) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CAH carries a Unified Composite Score of 42.7/100 (HOLD) at $272.81 (22.6x Forward P/E, 1.3% operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin). Composite vs. Pillar Nuance: While SNYR currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. CAH 42.7/100 HOLD), CAH captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (1.3% vs. -10.3% operating margin) and revenue trajectory (+5.5% vs. -32.8% YoY).

CAH leads the Growth & Scale pillar: CAH posts +5.5% YoY revenue growth and +26.6% YoY earnings growth on $257.8B TTM revenue (3.9% gross margin, 1.3% operating margin), compared with SNYR at -32.8% YoY revenue growth and -90.6% YoY earnings growth on $28M TTM revenue (65.4% gross margin, -10.3% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), CAH cumulative revenue shifted +74.7% while SNYR shifted +0.0%. In operating R&D and SG&A reinvestment, CAH deploys 2.6% of Rev ($6.70B) (0 90-day corporate R&D disclosures) versus 75.7% of Rev ($21M) (0 disclosures) for SNYR.

SNYR screens cheaper on headline valuation multiples. CAH trades at 22.6x Forward P/E, 35.2x Trailing P/E, 1.31x PEG, and 0.3x EV/Revenue (1.9% FCF margin), whereas SNYR trades at 0.6x Forward P/E, 0.6x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAH (0.0% ROE) versus SNYR (-361.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CAH carries 82.4% implied volatility (59th %ile, Balanced (25th–60th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (-0.03β · 24% Vol realized risk). By comparison, SNYR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.86β · 868% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.